Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Tenecteplase
- Used in
- Blood, clotting and anaemia
- Made by
- Boehringer Ingelheim International GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Boehringer Ingelheim International GmbH |
|---|---|
| Active substance | Tenecteplase |
| Used in | Blood, clotting and anaemia |
| Classification | B01AD · Blood, clotting and anaemia |
| Authorised on | 2001-02-23 |
| Last updated by the regulator | 2005-12-05 |
| EMA product number | EMEA/H/C/000307 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.